A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Site JP00029, Numakunai

Site JP00007, Aichi

Site JP00018, Aichi

Site JP00028, Aichi

Site JP00001, Chiba

Site JP00035, Ehime

Site JP00012, Fukui

Site JP00011, Fukuoka

Site JP00031, Fukuoka

Site JP00030, Hiroshima

Site JP00034, Hiroshima

Site JP00036, Hiroshima

Site JP00005, Hokkaido

Site JP00020, Hyōgo

Site JP00015, Ibaraki

Site JP00017, Ibaraki

Site JP00021, Ibaraki

Site JP00025, Ibaraki

Site JP00037, Ibaraki

Site JP00033, Ishikawa

Site JP00006, Kanagawa

Site JP00014, Kanagawa

Site JP00038, Kanagawa

Site JP00010, Miyagi

Site JP00016, Nagano

Site JP00024, Niigata

Site JP00003, Osaka

Site JP00009, Osaka

Site JP00026, Osaka

Site JP00032, Ōita

Site JP00002, Saitama

Site JP00019, Saitama

Site JP00027, Saitama

Site JP00004, Tokyo

Site JP00013, Tokyo

Site JP00022, Tokyo

Site JP00023, Tokyo

Site JP00008, Toyama